Skip to main content
SpringerLink
Log in

Chronic Lymphocytic Leukemia

  • Chapter
  • First Online:
Molecular Aspects of Hematologic Malignancies

Part of the book series: Principles and Practice ((PRINCIPLES))

  • 1409 Accesses

Abstract

Human chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world. CLL has long been believed to be a single disease, but recent insights underline the biological and clinical heterogeneity of CLL. Recognition of CLL subgroups with a completely different pathophysiology and clinical course, has paved the way to better define high-risk CLL patients based on prognostic factors, to predict response to therapy, and to estimate progression-free and overall survival. Moreover, knowledge of different aspects of the (immuno) pathogenesis of CLL (genomic and epigenetic aberrations, antigenic stimulation, microenvironmental stimuli) has greatly increased. These insights are key to further develop preventive strategies and to design innovative therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andritsos LA, Byrd JC, Hewes B, Kipps TJ, Johns D, Burger JA (2010) Preliminary results from a phase I/II dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Haematologica 95:A772

    Google Scholar 

  • Austen B, Skowronska A, Baker C, Powel JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM, Moss PA, Stankovic T (2007) Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 25:5448–5457

    Article  PubMed  CAS  Google Scholar 

  • Belessi CJ, Davi FB, Stamatopoulos KE, Degano M, Andreou TM, Moreno C, Merle-Béral H, Crespo M, Laoutaris NP, Montserrat E, Caligaris-Cappio F, Anagnostopoulos AZ, Ghia P (2006) IGHV gene insertions and deletions in chronic lymphocytic leukemia: “CLL-biased” deletions in a subset of cases with stereotyped receptors. Eur J Immunol 36:1963–1974

    Article  PubMed  CAS  Google Scholar 

  • Blair A, Purue MP, Weisenburger DD, Baris D (2007) Chemical exposures and risk of chronic lymphocytic leukemia. Br J Haematol 139:753–761

    Article  PubMed  CAS  Google Scholar 

  • Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, Rosenwald A (2009) High-level expression of T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurse like cell cocultures and after BCR stimulation. Blood 113:3050–3058

    Article  PubMed  CAS  Google Scholar 

  • Burger JA (2011) Mechanisms of leukemia cell trafficking, homing, and tissue retention in CLL. Hematol Education 5:91–99

    Google Scholar 

  • Chiorazzi N, Ferrarini M (2011) Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117:1781–1791

    Article  PubMed  CAS  Google Scholar 

  • Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529

    Article  PubMed  CAS  Google Scholar 

  • Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, Hervé M, Meffre E, Oscier DG, Vlassara H, Scofield RH, Chen Y, Allen SL, Kolitz J, Rai KR, Chu CC, Chiorazzi N (2008) Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 14:665–674

    Article  PubMed  CAS  Google Scholar 

  • Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, Wang XB, Fales HM, Allen SL, Kolitz JE, Rai KR, Chiorazzi N (2008) Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122–5129

    Article  PubMed  CAS  Google Scholar 

  • Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutues E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS (2010) Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 42:132–136

    Article  PubMed  CAS  Google Scholar 

  • Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847

    PubMed  CAS  Google Scholar 

  • Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N, Moreno C, Anagnostopoulos A, Jurlander J, Tsaftaris A, Chiorazzi N, Belessi C, Ghia P, Rosenquist R, Davi F, Stamatopoulos K (2010) A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia 24:125–132

    Article  PubMed  CAS  Google Scholar 

  • Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman AM, Sunter NJ, Hall AG, Dyer MJS, Matutues E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Hillmen P, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston RS (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40:1204–1210

    Article  PubMed  Google Scholar 

  • Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017–1029

    Article  PubMed  CAS  Google Scholar 

  • Döhner H, Stilgenbauer S, Benner A, Leupot E, Krober A, Bullinger L, Döhner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916

    Article  PubMed  Google Scholar 

  • Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL study group CLL3X trial. Blood 116:2438–2447

    Article  PubMed  CAS  Google Scholar 

  • Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW Jr, Ferrarini M, Chiorazzi N (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515–1525

    Article  PubMed  CAS  Google Scholar 

  • Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578–2585

    Article  PubMed  CAS  Google Scholar 

  • Ganster C, Neesen J, Zehetmeyer S, Jager U, Esterbauer H, Mannhalter C, Kluge B, Fonatsch C (2009) DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosom Cancer 48:760–767

    Article  PubMed  CAS  Google Scholar 

  • Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, Michel A, Crespo M, Laoutaris N, Montserrat E, Anagnostopoulos A, Dighiero G, Fassas A, Caligaris-Cappio F, Davi F (2005) Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 105:1678–1685

    Article  PubMed  CAS  Google Scholar 

  • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456

    Article  PubMed  CAS  Google Scholar 

  • Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854

    PubMed  CAS  Google Scholar 

  • Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer S, Jäger U (2005) High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 19:1216–1223

    Article  PubMed  CAS  Google Scholar 

  • Hervé M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E (2005) Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115:1636–1643

    Article  PubMed  Google Scholar 

  • Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075–13080

    Article  PubMed  CAS  Google Scholar 

  • Johnson TA, Rassenti LZ, Kipps TJ (1997) Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158:235–246

    PubMed  CAS  Google Scholar 

  • Kanduri M, Cahill N, Goransson H, Enström C, Ryan F, Isaksson A, Rosenquist R (2010) Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 115:296–305

    Article  PubMed  CAS  Google Scholar 

  • Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA (1989) Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 86:5913–5917

    Article  PubMed  CAS  Google Scholar 

  • Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogenous phenotype related to memory B cells. J Exp Med 194:1625–1638

    Article  PubMed  CAS  Google Scholar 

  • Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, Dalla-Favera R (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28–40

    Article  PubMed  CAS  Google Scholar 

  • Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410–1416

    PubMed  Google Scholar 

  • Lannuti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3 K signalling and cellular viability. Blood 117:591–594

    Article  Google Scholar 

  • Lin K, Manocha S, Harris RJ, Matrai Z, Sherrington PD, Pettitt AR (2003) High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 102:1145–1146

    Article  PubMed  CAS  Google Scholar 

  • Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, Hamann D, Van Lier RA, Van Oers MH (2003) Expansion of CMV-specific CD8 + CD45RA + CD27- T-cells in B-cell chronic lymphocytic leukemia. Blood 102:1057–1063

    Article  PubMed  CAS  Google Scholar 

  • Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK (2007) Reversible anergy of sIgM-mediated signaling in two subsets of CLL defined by VH-gene mutational status. Blood 109:4424–4431

    Article  PubMed  CAS  Google Scholar 

  • Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, Caligaris-Cappio F, Vaur D, Ouzounis C, Belessi C, Ghia P, Davi F, Rosenquist R, Stamatopoulos K (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111:1524–1533

    Article  PubMed  CAS  Google Scholar 

  • Ocana E, Delgado-Perez L, Campos-Caro A, Munoz J, Paz A, Franco R, Brieva JA (2007) The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 92:349–356

    Article  PubMed  Google Scholar 

  • Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, Kimura EY, Bechet S, Dumas G, Brissard M, Merle-Béral H, Yamamoto M, Dighiero G, Davi F (2005) The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 106:650–657

    Article  PubMed  CAS  Google Scholar 

  • Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK (2003) Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood 101:3082–3084

    Article  PubMed  CAS  Google Scholar 

  • Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, Fredrickson T, Landgraf P, Ramachandra S, Huppi K, Toro JR, Zenger VE, Metcalf RA, Marti GE (2007) Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109:5079–5086

    Article  PubMed  CAS  Google Scholar 

  • Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639–1647

    Article  PubMed  CAS  Google Scholar 

  • Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS (2006) Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 108:638–644

    Article  PubMed  CAS  Google Scholar 

  • Schroeder HW Jr, Dighiero G (1994) The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 15:288–294

    Article  PubMed  CAS  Google Scholar 

  • Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJS, Jønsson V, Langerak AW, Mauro FR, Fuller S, Wiley J, Lyttelton M, Callea V, Yuille M, Catovsky D, Houlston RS (2005) A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia susceptibility loci. Am J Hum Genet 77:420–429

    Article  PubMed  CAS  Google Scholar 

  • Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O’Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA (2011) CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117:1662–1669

    Article  PubMed  CAS  Google Scholar 

  • Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Béral H, Ghia P, Davi F (2007) Over 20 % of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109:259–270

    Article  PubMed  CAS  Google Scholar 

  • Stamatopoulos K (2009) Stereotyped B cell receptors in CLL. In: Ghia P, Rosenquist R, Davi F (eds) Immunoglobulin gene analysis in chronic lymphocytic leukemia. Wolters Kluwer Health Italy Ltd, Milan, pp 95–111

    Google Scholar 

  • Sutton LA, Kostareli E, Hadzidimitriou A, Darzentas N, Tsaftaris A, Anagnostopoulos A, Rosenquist R, Stamatopoulos K (2009) Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. Blood 114:4460–4468

    Article  PubMed  CAS  Google Scholar 

  • Thorsélius M, Kröber A, Murray F, Thunberg U, Tobin G, Bühler A, Kienle D, Albesiano E, Maffei R, Dao-Ung LP, Wiley J, Vilpo J, Laurell A, Merup M, Roos G, Karlsson K, Chiorazzi N, Marasca R, Döhner H, Stilgenbauer S, Rosenquist R (2006) Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-utilizing chronic lymphocytic leukemia independent of geographical origin and mutational status. Blood 107:2889–2894

    Article  PubMed  Google Scholar 

  • Tobin G, Thunberg U, Johnson A, Thörn I, Söderberg O, Hultdin M, Botling J, Enblad G, Sällström J, Sundström C, Roos G, Rosenquist R (2002) Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262–2264

    Article  PubMed  CAS  Google Scholar 

  • Tobin G, Thunberg U, Johnson A, Eriksson I, Söderberg O, Karlsson K, Merup M, Juliusson G, Vilpo J, Enblad G, Sundström C, Roos G, Rosenquist R (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3 s: implicating recognition of a common antigen epitope. Blood 101:4952–4957

    Article  PubMed  CAS  Google Scholar 

  • Widhopf GF 2nd, Kipps TJ (2001) Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol 166:95–102

    PubMed  CAS  Google Scholar 

  • Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ (2000) CD40 ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96:2917–2924

    PubMed  CAS  Google Scholar 

  • Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749–1755

    Article  PubMed  CAS  Google Scholar 

  • Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer 10:37–50

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 50, 3015, GE, Rotterdam, The Netherlands

    Anton W. Langerak & Yorick Sandberg

  2. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    Yorick Sandberg

Authors
  1. Anton W. Langerak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yorick Sandberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anton W. Langerak .

Editor information

Editors and Affiliations

  1. International Institute of Molecular and, Trojdena 4, Warszawa, 02-109, Poland

    Michal Witt

  2. , Institute of Human Genetics, Polish Academy of Sciences, ul. Strzeszynska 32, Poznan, 60479, Poland

    Malgorzata Dawidowska

  3. , Department of Pediatric Hematology, Silesian Academy of Medicine, 3 Maja 13-15, Zabrze, 41800, Poland

    Tomasz Szczepanski

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Langerak, A.W., Sandberg, Y. (2012). Chronic Lymphocytic Leukemia. In: Witt, M., Dawidowska, M., Szczepanski, T. (eds) Molecular Aspects of Hematologic Malignancies. Principles and Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29467-9_5

Download citation

Publish with us

Policies and ethics

Search

Navigation